Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20287616 | 0.83 | SIGMAR1 (0.39) | SIGMAR1MLYCDALDH1A1POLBUSP2 | |
| SCHEMBL17368483 | 0.80 | SIGMAR1 (0.44) | SIGMAR1GAAMLYCDALDH1A1CCKBR | |
| SCHEMBL24690507 | 0.80 | SIGMAR1 (0.44) | SIGMAR1GAAMLYCDALDH1A1POLB | |
| SCHEMBL12656584 | 0.80 | SIGMAR1 (0.44) | SIGMAR1GAAMLYCDALDH1A1CCKBR | |
| SCHEMBL23589877 | 0.80 | GAA (0.52) | GAAALDH1A1POLBHPGD | |
| SCHEMBL23589878 | 0.77 | GAA (0.43) | GAAALDH1A1HPGD | |
| SCHEMBL18897122 | 0.77 | SIGMAR1 (0.41) | SIGMAR1MLYCDALDH1A1HPGD | |
| SCHEMBL16137445 | 0.77 | PTGS1 (0.38) | GAAALDH1A1POLBHPGD | |
| SCHEMBL18313748 | 0.76 | MEN1 (0.49) | GAAALDH1A1POLBHPGD | |
| SCHEMBL10224055 | 0.76 | SMN1; SMN2 (0.49) | SIGMAR1GAAMLYCDALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | SIGMAR1 545/4885GAA 172/4885MLYCD 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.